A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

计划入组 8 人 · 首次发布于 2025 年 6 月 17 日

An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

计划入组 24 人 · 首次发布于 2026 年 7 月 15 日

Laparoscopic Partial Nephrectomy for cT1 Tumors

计划入组 292 人 · 首次发布于 2019 年 12 月 30 日

EYS-611

CT1-DAP001

PST-3093

Phloronol, Inc.

United States

Pola Chemical Industries, Inc.

Japan

SpliSense Ltd.

Israel

PulseSight Therapeutics Doses First Patient in Phase I Trial of PST-611 for Dry AMD

PulseSight Therapeutics Advances PST-611 for Dry AMD/Geographic Atrophy into Phase I Trial

PulseSight Therapeutics Initiates Clinical Development of Novel Transferrin Therapy for Geographic Atrophy